CTXR · Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals' Q2 fiscal 2026 results highlight early commercial traction from the December 2025 LYMPHIR launch at subsidiary Citius Oncology, generating $1.7M net revenue in the quarter and $5.6M for the first half at robust 80% gross margins. Revenue dipped quarter-over-quarter due to large initial distributor orders in Q1, but repeat orders emerged and patients shifted to community centers, signaling scaling potential. Payer access advanced to near 100% of commercial lives with 83% of target accounts in formulary processes and zero denials, building a strong reimbursement foundation. R&D expenses fell 58% YoY to $1.6M as LYMPHIR pre-launch costs eased, though G&A ballooned to $26.4M from a $19.7M one-time CMO cancellation, driving the net loss to $21.2M or $(0.95)/share versus $10.9M last year. Post-quarter, $41.5M in funding—$5M Citius Pharma direct offering, $11.5M Oncology warrant exercises, and $25M Avenue debt (with $10M drawn)—bolsters runway through November 2026 and funds sales force expansion. Positive Phase 1 combo data with pembrolizumab and CAR-T, plus Europe shipments, expand LYMPHIR's platform potential amid ongoing Mino-Lok and Halo-Lido FDA engagements.